Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study

Robert DiBianco, John O. Parker, Simon Chakko, Paul H. Tanser, George Emmanuel, Jang B. Singh, Anthony Marlon

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF). After a stabilization period of at least 2 weeks with digitalis and diuretics, 73 patients with chronic CHF were randomized to receive additionally either doxazosin or placebo in double-blind fashion. Patients underwent weekly dose adjustments with increasing doses of doxazosin (1, 2, 4, 8, and 16 mg daily) or placebo for 5 weeks, and 67 were evaluated for 12 additional weeks on maximally tolerated doses of blinded study drugs. Treatment groups were evaluated with respect to symptoms of heart failure, indexes of quality of life and left ventricular function, frequency and type of arrhythmia, adverse events, and mortality rates. Doxazosin (11.9 ± 0.9 mg) given once daily produced a favorable trend in the investigators' and patients' assessments of symptomatic change. Doxazosin was associated with a significantly higher level of voluntary submaximal exercise and a favorable trend on left ventricular ejection fraction (increase of 9.8% of the baseline value vs 2.7% with placebo; p = NS). During the 3-month steady-dosing period, patients treated with doxazosin had a significant (p < 0.004) reduction in ventricular arrhythmias and significantly fewer morbid and mortal cardiac events (including episodes of worsening heart failure severe enough to prompt discontinuation of the study, myocardial infarction, and death). Doxazosin was well tolerated, producing no major side effects and only a slightly higher frequency of minor treatment-related side effects compared with placebo (p = NS). These findings suggest that doxazosin, in the dosages tested, may be helpful adjunctive treatment for patients with CHF who remain symptomatic with digitalis and diuretics.

Original languageEnglish
Pages (from-to)372-380
Number of pages9
JournalAmerican Heart Journal
Volume121
Issue number1 PART 2
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Doxazosin
Heart Failure
Placebos
Digitalis
Therapeutics
Diuretics
Cardiac Arrhythmias
Maximum Tolerated Dose
Left Ventricular Function
Stroke Volume
Oral Administration
Myocardial Infarction
Quality of Life
Research Personnel
Exercise
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

DiBianco, R., Parker, J. O., Chakko, S., Tanser, P. H., Emmanuel, G., Singh, J. B., & Marlon, A. (1991). Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study. American Heart Journal, 121(1 PART 2), 372-380. https://doi.org/10.1016/0002-8703(91)90875-I

Doxazosin for the treatment of chronic congestive heart failure : Results of a randomized double-blind and placebo-controlled study. / DiBianco, Robert; Parker, John O.; Chakko, Simon; Tanser, Paul H.; Emmanuel, George; Singh, Jang B.; Marlon, Anthony.

In: American Heart Journal, Vol. 121, No. 1 PART 2, 01.01.1991, p. 372-380.

Research output: Contribution to journalArticle

DiBianco, R, Parker, JO, Chakko, S, Tanser, PH, Emmanuel, G, Singh, JB & Marlon, A 1991, 'Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study', American Heart Journal, vol. 121, no. 1 PART 2, pp. 372-380. https://doi.org/10.1016/0002-8703(91)90875-I
DiBianco, Robert ; Parker, John O. ; Chakko, Simon ; Tanser, Paul H. ; Emmanuel, George ; Singh, Jang B. ; Marlon, Anthony. / Doxazosin for the treatment of chronic congestive heart failure : Results of a randomized double-blind and placebo-controlled study. In: American Heart Journal. 1991 ; Vol. 121, No. 1 PART 2. pp. 372-380.
@article{fbbcf63707c5487f92bfdd30e0a6b534,
title = "Doxazosin for the treatment of chronic congestive heart failure: Results of a randomized double-blind and placebo-controlled study",
abstract = "In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF). After a stabilization period of at least 2 weeks with digitalis and diuretics, 73 patients with chronic CHF were randomized to receive additionally either doxazosin or placebo in double-blind fashion. Patients underwent weekly dose adjustments with increasing doses of doxazosin (1, 2, 4, 8, and 16 mg daily) or placebo for 5 weeks, and 67 were evaluated for 12 additional weeks on maximally tolerated doses of blinded study drugs. Treatment groups were evaluated with respect to symptoms of heart failure, indexes of quality of life and left ventricular function, frequency and type of arrhythmia, adverse events, and mortality rates. Doxazosin (11.9 ± 0.9 mg) given once daily produced a favorable trend in the investigators' and patients' assessments of symptomatic change. Doxazosin was associated with a significantly higher level of voluntary submaximal exercise and a favorable trend on left ventricular ejection fraction (increase of 9.8{\%} of the baseline value vs 2.7{\%} with placebo; p = NS). During the 3-month steady-dosing period, patients treated with doxazosin had a significant (p < 0.004) reduction in ventricular arrhythmias and significantly fewer morbid and mortal cardiac events (including episodes of worsening heart failure severe enough to prompt discontinuation of the study, myocardial infarction, and death). Doxazosin was well tolerated, producing no major side effects and only a slightly higher frequency of minor treatment-related side effects compared with placebo (p = NS). These findings suggest that doxazosin, in the dosages tested, may be helpful adjunctive treatment for patients with CHF who remain symptomatic with digitalis and diuretics.",
author = "Robert DiBianco and Parker, {John O.} and Simon Chakko and Tanser, {Paul H.} and George Emmanuel and Singh, {Jang B.} and Anthony Marlon",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0002-8703(91)90875-I",
language = "English",
volume = "121",
pages = "372--380",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1 PART 2",

}

TY - JOUR

T1 - Doxazosin for the treatment of chronic congestive heart failure

T2 - Results of a randomized double-blind and placebo-controlled study

AU - DiBianco, Robert

AU - Parker, John O.

AU - Chakko, Simon

AU - Tanser, Paul H.

AU - Emmanuel, George

AU - Singh, Jang B.

AU - Marlon, Anthony

PY - 1991/1/1

Y1 - 1991/1/1

N2 - In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF). After a stabilization period of at least 2 weeks with digitalis and diuretics, 73 patients with chronic CHF were randomized to receive additionally either doxazosin or placebo in double-blind fashion. Patients underwent weekly dose adjustments with increasing doses of doxazosin (1, 2, 4, 8, and 16 mg daily) or placebo for 5 weeks, and 67 were evaluated for 12 additional weeks on maximally tolerated doses of blinded study drugs. Treatment groups were evaluated with respect to symptoms of heart failure, indexes of quality of life and left ventricular function, frequency and type of arrhythmia, adverse events, and mortality rates. Doxazosin (11.9 ± 0.9 mg) given once daily produced a favorable trend in the investigators' and patients' assessments of symptomatic change. Doxazosin was associated with a significantly higher level of voluntary submaximal exercise and a favorable trend on left ventricular ejection fraction (increase of 9.8% of the baseline value vs 2.7% with placebo; p = NS). During the 3-month steady-dosing period, patients treated with doxazosin had a significant (p < 0.004) reduction in ventricular arrhythmias and significantly fewer morbid and mortal cardiac events (including episodes of worsening heart failure severe enough to prompt discontinuation of the study, myocardial infarction, and death). Doxazosin was well tolerated, producing no major side effects and only a slightly higher frequency of minor treatment-related side effects compared with placebo (p = NS). These findings suggest that doxazosin, in the dosages tested, may be helpful adjunctive treatment for patients with CHF who remain symptomatic with digitalis and diuretics.

AB - In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF). After a stabilization period of at least 2 weeks with digitalis and diuretics, 73 patients with chronic CHF were randomized to receive additionally either doxazosin or placebo in double-blind fashion. Patients underwent weekly dose adjustments with increasing doses of doxazosin (1, 2, 4, 8, and 16 mg daily) or placebo for 5 weeks, and 67 were evaluated for 12 additional weeks on maximally tolerated doses of blinded study drugs. Treatment groups were evaluated with respect to symptoms of heart failure, indexes of quality of life and left ventricular function, frequency and type of arrhythmia, adverse events, and mortality rates. Doxazosin (11.9 ± 0.9 mg) given once daily produced a favorable trend in the investigators' and patients' assessments of symptomatic change. Doxazosin was associated with a significantly higher level of voluntary submaximal exercise and a favorable trend on left ventricular ejection fraction (increase of 9.8% of the baseline value vs 2.7% with placebo; p = NS). During the 3-month steady-dosing period, patients treated with doxazosin had a significant (p < 0.004) reduction in ventricular arrhythmias and significantly fewer morbid and mortal cardiac events (including episodes of worsening heart failure severe enough to prompt discontinuation of the study, myocardial infarction, and death). Doxazosin was well tolerated, producing no major side effects and only a slightly higher frequency of minor treatment-related side effects compared with placebo (p = NS). These findings suggest that doxazosin, in the dosages tested, may be helpful adjunctive treatment for patients with CHF who remain symptomatic with digitalis and diuretics.

UR - http://www.scopus.com/inward/record.url?scp=0026078060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026078060&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(91)90875-I

DO - 10.1016/0002-8703(91)90875-I

M3 - Article

C2 - 1670746

AN - SCOPUS:0026078060

VL - 121

SP - 372

EP - 380

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1 PART 2

ER -